Allogene Therapeutics Inc (ALLO)

NASDAQ
16.74
-0.51(-2.96%)
  • Volume:
    444,437
  • Day's Range:
    16.72 - 17.39
  • 52 wk Range:
    6.43 - 27.86

ALLO Overview

Prev. Close
17.25
Day's Range
16.72-17.39
Revenue
247K
Open
17.13
52 wk Range
6.43-27.86
EPS
-2.19
Volume
444,437
Market Cap
2.41B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,019,595
P/E Ratio
-7.86
Beta
0.548
1-Year Change
-19.54%
Shares Outstanding
143,806,825
Next Earnings Date
Nov 09, 2022
What is your sentiment on Allogene Therapeutics?
or
Vote to see community's results!

Allogene Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Allogene Therapeutics Inc Analysis

Allogene Therapeutics Inc Company Profile

Allogene Therapeutics Inc Company Profile

Employees
301

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralStrong BuyNeutral
Technical IndicatorsStrong SellStrong SellSellStrong BuySell
SummaryStrong SellStrong SellNeutralStrong BuyNeutral
  • Bought it recently. Planning to hold until $26 good idea?
    2
    • There is still a gap to fill imo at 15,96
      0
    • What do you mean? (sorry i am a noob)
      0
    • Alpha RomeoA gap on a chart is considered to be filled when the price action moves back through the open gap area where transactions were missing. Check the 15,96 level on the chart.
      0
  • SOLD #ALLO @ 14.51000000
    0
    • Nice one today!
      0
      • This is running great
        0
        • cashed out at 17,22
          0
      • buy buy buy
        0
        • getting my 🚀🚀🚀🚀🚀🚀🚀🌋🙀
          0
          • at this price is Christmas
            1
            • Epic fall!
              0
              • I mean yes
                1
                • no comments! weird! dont you think this is a promising stock?
                  0